Performance of a Nomogram Predicting Disease-Specific Survival After an R0 Resection for Gastric Cancer in Patients Receiving Postoperative Chemoradiation Therapy
- 8 January 2014
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 88 (3) , 624-629
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Gastric CancerJournal of the National Comprehensive Cancer Network, 2010
- A Phase I–II Study of Postoperative Capecitabine-Based Chemoradiotherapy in Gastric CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Postoperative chemoradiotherapy in gastric cancer – a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapyBritish Journal of Cancer, 2007
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Postoperative Nomogram for Disease-Specific Survival After an R0 Resection for Gastric CarcinomaJournal of Clinical Oncology, 2003
- Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal JunctionNew England Journal of Medicine, 2001
- The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomyCancer, 2000
- A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinomaCancer, 1982